drugset / Trial / NCT01508572
VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively.
Timeline
- Start
- 2011-10
- Primary completion
- 2014-11
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab-IRDye800CW | Monoclonal antibody | 4.5 mg | Intravenous |